Market Insight on Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

To view the table of contents and know more details, please visit ​Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
- The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Acucela Inc. Amarantus Bioscience Holdings, Inc. Amgen Inc. Applied Genetic Technologies Corporation Asklepios BioPharmaceutical, Inc. Astellas Pharma Inc. Caladrius Biosciences, Inc. Dompe Farmaceutici S.p.A. Genable Technologies Limited Genethon GenSight Biologics S.A. Grupo Ferrer Internacional, S.A. ID Pharma Co., Ltd. InFlectis BioScience International Stem Cell Corporation Ionis Pharmaceuticals, Inc. M's Science Corporation Mimetogen Pharmaceuticals Inc. Nanovector s.r.l. Orphagen Pharmaceuticals, Inc. QLT Inc. RegenxBio Inc. ReNeuron Group Plc SanBio, Inc. Sanofi Shire Plc Spark Therapeutics, Inc. Staidson (Beijing) Biopharmaceuticals Co., Ltd. Sucampo Pharmaceuticals, Inc. Sun Pharma Advanced Research Company Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###